In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen

Abstract

There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, nonspecific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia. This study reports the potent in vitro activity of solithromycin against a collection of recent isolates of Bordetella pertussis.

Pertussis Reinfection in an Adult: A Cause of Persistent Cough Not to Be Ignored

“…Appropriate antibiotic treatment can eliminate Bordetella pertussis from the respiratory tract and, consequently, prevent transmission to susceptible contacts. Furthermore, it has been proved that antibiotics decrease the probability of secondary bacterial infections and reduce duration and severity of symptoms, when given early in the course of the disease [ 17 ].…”

Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy

“… Note: Data from Barrera et al 10 , File et al 11 , Hook et al 12 , Oldach et al 13 , Couldwell and Lewis 16 , Keelan et al 17 , Rodgers et al 32 , Piccinelli et al 36 , Farrell et al 37 , Farrell et al 38 , Jensen et al 39 , Mallegol et al 40 , Furfaro et al 41 , Hardy et al 42 , and Weintraub et al 43 Abbreviations: MRSA, methicillin-resistant S. aureus ; MSSA, methicillin-sensitive S. aureus . …”